Literature DB >> 7542786

Risperidone augmentation of clozapine.

R H McCarthy1, K G Terkelsen.   

Abstract

While effective as a single agent in a significant proportion of treatment refractory patients, clozapine is often used in combination with other medications, including classical neuroleptics (1), mood stabilizers and antidepressants (2), benzodiazepines (3) and lithium (4). In Denmark, where clozapine has been in near continuous use since 1975, up to 60% of clozapine patients receive additional medication (4). Classical neuroleptics, often at antipsychotic levels, are the medications most frequently added, and are used in 30-35% of patients receiving clozapine (4,5). Clozapine, due to its low D2-blocking effect, may be therapeutically insufficient to contain symptoms and additional agents may be required (4). In controlled clinical trials risperidone has been shown to be superior to haloperidol (6), but has not yet been rigorously compared to clozapine. In light of its established efficacy and pharmacological profile (7) risperidone may be reasonably construed to be a medication with efficacy somewhere between clozapine and classical neuroleptics. As such, it may be especially well suited for use with clozapine as a part of an augmentation strategy. There are no reports in the literature describing the concurrent use of risperidone and clozapine. We present two cases demonstrating augmentation of clozapine's effects through combined use with clozapine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542786     DOI: 10.1055/s-2007-979590

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  10 in total

1.  Aripiprazole augmentation of clozapine: in refractory schizophrenia.

Authors:  Adam Keller Ashton
Journal:  Psychiatry (Edgmont)       Date:  2005-02

Review 2.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 3.  Augmentation strategies in clozapine-resistant schizophrenia.

Authors:  Gary Remington; Amitabha Saha; Siow-Ann Chong; Chekkera Shammi
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

Review 5.  Risperidone augmentation of clozapine: a critical review.

Authors:  Vassilis P Kontaxakis; Panayotis P Ferentinos; Beata J Havaki-Kontaxaki; Konstantinos G Paplos; Dimitra A Pappa; George N Christodoulou
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08-08       Impact factor: 5.270

Review 6.  Clinically significant interactions of psychotropic agents with antipsychotic drugs.

Authors:  M C Meyer; R J Baldessarini; D C Goff; F Centorrino
Journal:  Drug Saf       Date:  1996-11       Impact factor: 5.606

Review 7.  Treatment refractory schizophrenia: how should we proceed?

Authors:  Z A Sharif
Journal:  Psychiatr Q       Date:  1998

8.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

9.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

10.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.